Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Receivables (2020 - 2023)

Immuneering has reported Change in Receivables over the past 4 years, most recently at -$1046.0 for Q2 2023.

  • Quarterly results put Change in Receivables at -$1046.0 for Q2 2023, up 98.97% from a year ago — trailing twelve months through Mar 2024 was -$1046.0 (up 99.62% YoY), and the annual figure for FY2023 was -$12417.0, up 94.69%.
  • Change in Receivables for Q2 2023 was -$1046.0 at Immuneering, up from -$11371.0 in the prior quarter.
  • Over the last five years, Change in Receivables for IMRX hit a ceiling of $278185.0 in Q3 2020 and a floor of -$250978.0 in Q4 2021.
  • Median Change in Receivables over the past 4 years was -$17550.5 (2021), compared with a mean of -$27133.6.
  • Peak annual rise in Change in Receivables hit 535.73% in 2022, while the deepest fall reached 3847.7% in 2022.
  • Immuneering's Change in Receivables stood at -$78035.0 in 2020, then plummeted by 221.62% to -$250978.0 in 2021, then soared by 76.98% to -$57763.0 in 2022, then skyrocketed by 98.19% to -$1046.0 in 2023.
  • The last three reported values for Change in Receivables were -$1046.0 (Q2 2023), -$11371.0 (Q1 2023), and -$57763.0 (Q4 2022) per Business Quant data.